Chiltern Partners with Karolinska Development
Chiltern International Limited proudly announces partnership with Karolinska Development in Sweden
Chiltern International Limited (Chiltern), a global contract research organization (CRO), proudly announces our partnership with Karolinska Development in Sweden, a life science investment company listed on NASDAQ OMX Stockholm (ticker: KDEV). Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations.
“We are extremely pleased to be selected as the partner CRO for Karolinska Development after an extensive CRO selection process in 2012. We were selected based on our compatibility with Karolinska Development’s specific development needs in terms of our global company infrastructure and our approach to deliver innovation, quality and flexibility to every project” stated Dr Jim Esinhart, CEO of Chiltern.
Aize Smink, Chiltern’s Chief Operating Officer, commented “We are honored and proud to be partnering with Karolinska Development, a world class organization committed to life science innovations and bringing novel therapies to market. A key aspect of our partnering is our early involvement in the development of studies and providing support services and consultation as needed in the product lifecycle. Together, we will work closely with the core team at Karolinska Development to achieve the goals and objectives of their pipeline.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
